| Title |
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
|
|---|---|
| Published in |
OncoTargets and therapy, July 2013
|
| DOI | 10.2147/ott.s45906 |
| Pubmed ID | |
| Authors |
Yasser Abdel Kader, Thierry Le Chevalier, Tamer El-Nahas, Amr Sakr |
| Abstract |
The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 9% |
| Unknown | 21 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 22% |
| Student > Ph. D. Student | 3 | 13% |
| Other | 2 | 9% |
| Lecturer | 1 | 4% |
| Student > Doctoral Student | 1 | 4% |
| Other | 5 | 22% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 57% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Neuroscience | 1 | 4% |
| Unspecified | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2013.
All research outputs
#22,778,604
of 25,394,764 outputs
Outputs from OncoTargets and therapy
#2,080
of 3,016 outputs
Outputs of similar age
#183,691
of 206,773 outputs
Outputs of similar age from OncoTargets and therapy
#36
of 42 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,773 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.